Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity
Ophthalmology Retina · 2025-08 · 9 (8) · 807-811
DOI: 10.1016/j.oret.2025.02.009 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Ophthalmology Retina, 2025-08. Verfasst von Thomas W Hejkal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eye Consultants, Omaha, Nebraska. Hauptthemen laut MEDLINE: Bevacizumab, Retinopathy of Prematurity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Consultants, Omaha, Nebraska.
- Division of Ophthalmology, Children's Hospital and Medical Center, Omaha, Nebraska; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska.
- Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska.
- Division of Ophthalmology, Children's Hospital and Medical Center, Omaha, Nebraska; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska. Electronic address: prychwalski@childrensnebraska.…
Zitieren
APA
Hejkal, T. W., Sinha, S., Rishi, P., Jain, S. F., & Rychwalski, P. J. (2025). Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity. Ophthalmology Retina, 9(8), 807-811. https://doi.org/10.1016/j.oret.2025.02.009
Vancouver
Hejkal TW, Sinha S, Rishi P, Jain SF, Rychwalski PJ. Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity. Ophthalmology Retina. 2025;9(8):807-811. doi:10.1016/j.oret.2025.02.009
BibTeX
@article{Hejkal2025,
author = {Hejkal, Thomas W and Sinha, Shruti and Rishi, Pukhraj and Jain, Samiksha F and Rychwalski, Paul J},
title = {Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity},
journal = {Ophthalmology Retina},
year = {2025},
volume = {9},
number = {8},
pages = {807--811},
doi = {10.1016/j.oret.2025.02.009}
}
EUVIMED